NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a proposed underwritten public offering of its common stock, intending to use the net proceeds for working capital and general corporate purposes. The offering includes a 30-day option for the underwriter to purchase an additional 15% of the shares sold. The offering is subject to market conditions and may not be completed as planned. Craig-Hallum Capital Group acts as the sole underwriter. The public offering is made under an effective shelf registration statement as filed with the SEC on June 14, 2021.

Positive

• Proceeds from the offering will be used for working capital and corporate purposes.

Negative

• Proposed offering could lead to shareholder dilution.
• Completion of the offering is uncertain due to market conditions.

EDEN PRAIRIE, Minn., Oct. 12, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has commenced a proposed underwritten registered public offering of shares of its common stock.

All of the shares of common stock to be sold in the proposed offering will be sold by the Company. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from this proposed offering for working capital and other general corporate purposes. 

Craig-Hallum Capital Group is acting as the sole managing underwriter for the proposed offering.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-256830) that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on June 14, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Attn: Equity Capital Markets, telephone: 612-334-6300 or by email at prospectus@chlm.com.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements include statements related to the proposed offering and expected use of proceeds. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering, the impact of general economic, industry or political conditions in the United States or internationally and those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-proposed-public-offering-of-common-stock-301398697.html

SOURCE NeuroOne Medical Technologies Corporation

FAQ

What is the purpose of NeuroOne's proposed public offering on October 12, 2021?

NeuroOne aims to use the proceeds from the public offering for working capital and other general corporate purposes.

What is the size of NeuroOne's proposed public offering?

The proposed offering includes a 30-day option for the underwriter to purchase up to an additional 15% of the shares sold.

Who is underwriting NeuroOne's public offering?

Craig-Hallum Capital Group is acting as the sole managing underwriter for the offering.

When was the registration statement for NeuroOne's offering declared effective?

The registration statement was declared effective by the SEC on June 14, 2021.

What risks are associated with NeuroOne's proposed public offering?

The offering is subject to market conditions and the actual size or terms may change, leading to uncertainty in completion.